Antisense protein kinase A RIα-induced tumor reversion:: portrait of a microarray

被引：20

作者：

Cho-Chung, YS ^{[1
]}

机构：

[1] NCI, Ctr Canc Res, Basic Res Lab, Cellular Biochem Sect, Bethesda, MD 20892 USA

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS | 2004年 / 1697卷 / 1-2期

关键词：

antisense; cancer chemotherapy; DNA microarray; gene expression; growth inhibition; oligonucleotide; protein kinase A;

D O I：

10.1016/j.bbapap.2003.11.014

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Antisense oligonucleotides can selectively block disease-causing genes due to the specificity of the Watson-Crick base-pairing mechanism of action. A genome-wide view of antisense technology is illustrated via protein kinase A RIalpha antisense. Complementary DNA microarray analysis of the Met antisense-induced expression profile shows the up- and down-regulation of clusters of coordinately expressed genes that define the molecular portrait of a reverted tumor cell phenotype. This global view broadens the horizons of antisense technology; it advances the promise of antisense beyond a single target gene to the whole cell and the whole organism. Along with recent rapid advances in oligonucleotide tech no logies-including new chemical and biological understanding of more sophisticated nucleic acid drugsoligonucleotide-based iene silencing offers not only an exquisitely specific genetic tool for exploring basic science but also an exciting possibility for treating and preventing cancer and other diseases. (C) 2003 Elsevier B.V. All rights reserved.

引用

页码：71 / 79

页数：9

共 61 条

[1] Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies [J].

Agrawal, S ;

Jiang, ZW ;

Zhao, QY ;

Shaw, D ;

Cai, QY ;

Roskey, A ;

Channavajjala, L ;

Saxinger, C ;

Zhang, RW .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) :2620-2625

[2] Antisense oligonucleotides: Towards clinical trials [J].

Agrawal, S .

TRENDS IN BIOTECHNOLOGY, 1996, 14 (10) :376-387

[3] Antisense therapeutics [J].

Agrawal, S ;

Zhao, QY .

CURRENT OPINION IN CHEMICAL BIOLOGY, 1998, 2 (04) :519-528

[4] Mixed backbone oligonucleotides: Improvement in oligonucleotide-induced toxicity in vivo [J].

Agrawal, S ;

Zhao, Q .

ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1998, 8 (02) :135-139

[5]

Agrawal S., 1996, ANTISENSE THERAPEUTI

[6] In vivo studies with antisense oligonucleotides [J].

Akhtar, S ;

Agrawal, S .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (01) :12-18

[7] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].

Alizadeh, AA ;

Eisen, MB ;

Davis, RE ;

Ma, C ;

Lossos, IS ;

Rosenwald, A ;

Boldrick, JG ;

Sabet, H ;

Tran, T ;

Yu, X ;

Powell, JI ;

Yang, LM ;

Marti, GE ;

Moore, T ;

Hudson, J ;

Lu, LS ;

Lewis, DB ;

Tibshirani, R ;

Sherlock, G ;

Chan, WC ;

Greiner, TC ;

Weisenburger, DD ;

Armitage, JO ;

Warnke, R ;

Levy, R ;

Wilson, W ;

Grever, MR ;

Byrd, JC ;

Botstein, D ;

Brown, PO ;

Staudt, LM .

NATURE, 2000, 403 (6769) :503-511

[8] Protein kinase A-Iα subunit-directed antisense inhibition of ovarian cancer cell growth:: crosstalk with tyrosine kinase signaling pathway [J].

Alper, Ö ;

Hacker, NF ;

Cho-Chung, YS .

ONCOGENE, 1999, 18 (35) :4999-5004

[9]

BEEBE SJ, 1986, ENZYMES, V17, P43

[10] Antisense oligonucleotides: Is the glass half full or half empty? [J].

Bennett, CF .

BIOCHEMICAL PHARMACOLOGY, 1998, 55 (01) :9-19

← 1 2 3 4 5 6 7 →